Technical Analysis for PTN - Palatin Technologies, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | 3.90% | |
Wide Bands | Range Expansion | 3.90% | |
Oversold Stochastic | Weakness | 3.90% | |
New Downtrend | Bearish | 6.67% | |
NR7 | Range Contraction | 6.67% | |
Narrow Range Bar | Range Contraction | 6.67% | |
Wide Bands | Range Expansion | 6.67% | |
Down 3 Days in a Row | Weakness | 6.67% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 21 hours ago |
10 DMA Resistance | about 21 hours ago |
Up 5% | about 21 hours ago |
Up 10% | about 21 hours ago |
Up 3% | about 21 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/15/2024
Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Dysfunction Obesity Endocrine System Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction Treatment Of Obesity
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Dysfunction Obesity Endocrine System Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction Treatment Of Obesity
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.65 |
52 Week Low | 1.43 |
Average Volume | 597,252 |
200-Day Moving Average | 2.42 |
50-Day Moving Average | 3.12 |
20-Day Moving Average | 2.30 |
10-Day Moving Average | 1.72 |
Average True Range | 0.35 |
RSI (14) | 34.21 |
ADX | 26.49 |
+DI | 17.51 |
-DI | 31.68 |
Chandelier Exit (Long, 3 ATRs) | 3.00 |
Chandelier Exit (Short, 3 ATRs) | 2.54 |
Upper Bollinger Bands | 3.79 |
Lower Bollinger Band | 0.80 |
Percent B (%b) | 0.27 |
BandWidth | 130.34 |
MACD Line | -0.51 |
MACD Signal Line | -0.47 |
MACD Histogram | -0.046 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.92 | ||||
Resistance 3 (R3) | 1.92 | 1.83 | 1.86 | ||
Resistance 2 (R2) | 1.83 | 1.75 | 1.82 | 1.84 | |
Resistance 1 (R1) | 1.71 | 1.70 | 1.77 | 1.71 | 1.83 |
Pivot Point | 1.62 | 1.62 | 1.65 | 1.61 | 1.62 |
Support 1 (S1) | 1.50 | 1.54 | 1.56 | 1.50 | 1.37 |
Support 2 (S2) | 1.41 | 1.49 | 1.40 | 1.36 | |
Support 3 (S3) | 1.29 | 1.41 | 1.34 | ||
Support 4 (S4) | 1.29 |